earnings

Which pharmas grew most in Q2? AstraZeneca, Merck and BMS, for 3
Which pharmas grew most in Q2? AstraZeneca, Merck and BMS, for 3
Fierce Pharma
earnings
AstraZeneca
Merck
Bristol-Myers Squibb
Flag link:
What You'll Want to Know About Myriad Genetics' Disappointing Q4 Results
What You'll Want to Know About Myriad Genetics' Disappointing Q4 Results
Motley Fool
Myriad Genetics
earnings
Flag link:
Elanco Animal Health Beats Q2 Earnings Estimates but Faces Increasing Headwinds
Elanco Animal Health Beats Q2 Earnings Estimates but Faces Increasing Headwinds
Motley Fool
Elanco Health
earnings
animal health
Flag link:
AnaptysBio Prepares for a Potential Gear Shift
AnaptysBio Prepares for a Potential Gear Shift
Yahoo/Motley Fool
AnaptysBio
earnings
etokimab
Flag link:
Novo Nordisk's new diabetes, obesity drugs lift sales outlook
Novo Nordisk's new diabetes, obesity drugs lift sales outlook
Yahoo/Reuters
Novo Nordisk
earnings
Flag link:
Nektar Therapeutics stock drops after results
Nektar Therapeutics stock drops after results
Marketwatch
Nektar Therapeutics
earnings
Flag link:
Here's Why Puma Biotechnology Fell 24.1% in July
Here's Why Puma Biotechnology Fell 24.1% in July
Motley Fool
Puma Biotechnology
earnings
Flag link:
Celgene Continues Growing While Waiting for its Acquisition to Close
Celgene Continues Growing While Waiting for its Acquisition to Close
Motley Fool
Celgene
earnings
M&A
Bristol-Myers Squibb
Flag link:
BioMarin's Roller Coaster Continues
BioMarin's Roller Coaster Continues
Yahoo/Motley Fool
Biomarin
earnings
Flag link:
Allergan beats profit, raises revenue forecast on Restasis, Juvederm demand
Allergan beats profit, raises revenue forecast on Restasis, Juvederm demand
Yahoo/Reuters
Allergan
earnings
Flag link:
Abiomed Is Still in the Recovery Ward
Abiomed Is Still in the Recovery Ward
Motley Fool
Abiomed
earnings
Impella RP
devices
Flag link:
Bluebird Bio (BLUE) Reports Q2 Loss, Tops Revenue Estimates
Bluebird Bio (BLUE) Reports Q2 Loss, Tops Revenue Estimates
Yahoo/Zacks.com
Bluebird Bio
earnings
Flag link:
Boehringer posts solid first half as business revamp beds in
Boehringer posts solid first half as business revamp beds in
PM Live
Boehringer Ingelheim
earnings
Spiriva
Jardiance
Flag link:
Acadia, Neurocrine See Stock Price Bump After Quarterly Earnings
Acadia, Neurocrine See Stock Price Bump After Quarterly Earnings
Xconomy
earnings
Acadia
Neurocrine
Flag link:
Crysvita sales push Ultragenyx ahead for the quarter
Crysvita sales push Ultragenyx ahead for the quarter
BioCentury
Ultragenyx
Crysvita
earnings
Flag link:
Amarin boosted as another milestone to the FDA’s big Vascepa decision flies by with no sign of an AdCom
Amarin boosted as another milestone to the FDA’s big Vascepa decision flies by with no sign of an AdCom
Endpoints
FDA
Amarin
Vascepa
advisory panels
earnings
Flag link:
Celgene Offers Beat-And-Raise As Bristol Merger Looms Closer
Celgene Offers Beat-And-Raise As Bristol Merger Looms Closer
Investors Business Daily
Celgene
earnings
M&A
Bristol-Myers Squibb
Flag link:
Amgen results beat estimates, lung cancer trial planned
Amgen results beat estimates, lung cancer trial planned
Yahoo/Reuters
Amgen
earnings
clinical trials
lung cancer
AMG510
Flag link:
Gilead Sciences Reports Improving Revenue in the 2nd Quarter
Gilead Sciences Reports Improving Revenue in the 2nd Quarter
Motley Fool
Gilead Sciences
earnings
Biktarvy
Flag link:
Neurocrine Biosciences Posts Sizzling Sales Growth in Q2
Neurocrine Biosciences Posts Sizzling Sales Growth in Q2
Motley Fool
Neurocrine Biosciences
earnings
Flag link:

Pages